Asymmetric dimethylarginine (ADMA) a novel cardiovascular risk factor--evidence from epidemiological and prospective
Andrzej Szuba1, Maciej Podgórski
1Chair and Clinic of Internal and Occupational Diseases and Arterial Hypertension in Wrocław, Pasteura 4, PL 50-367 Wrocław, Poland. szubaa@yahoo.com
Abstract:
There is a growing clinical evidence to support the hypothesis that asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase is a new independent cardiovascular risk factor. ADMA mediates endothelial dysfunction in lipid disorders, coronary artery disease, chronic heart failure, diabetes mellitus and hypertension. The aim of this review was to summarize the latest evidence from epidemiological and prospective clinical trials and to emphasize the role of ADMAas a cardiovascular risk factor.
Related Concept Videos
Atherosclerosis III: Management
Coronary Artery Disease I: Introduction
Coronary Artery Disease IV: Preventive Measures
Hypertension III: Clinical Manifestations and Diagnostic Studies
